Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 244-248 , October 2008

Exploring the Possibility of Unique Molecular, Biological, and Tissue Effects With Hypofractionated Radiotherapy

References 

  1. Blomgren H, Lax I, Naslund I, et al. Stereotactic high dose fraction radiation therapy of extracranial tumors using an accelerator (Clinical experience of the first thirty-one patients). Acta Oncol. 1995;34:861–870
  2. Hiraoka M, Matsuo Y, Nagata Y. Stereotactic body radiation therapy (SBRT) for early-stage lung cancer. Cancer Radiother. 2007;11:32–35
  3. Timmerman R, Papiez L, McGarry R, et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest. 2003;124:1946–1955
  4. Jin L, Wang L, Li J, et al. Investigation of optimal beam margins for stereotactic radiotherapy of lung-cancer using Monte Carlo dose calculations. Phys Med Biol. 2007;52:3549–3561
  5. Cardinale RM, Wu Q, Benedict SH, et al. Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. Int J Radiat Oncol Biol Phys. 1999;45:515–520
  6. Giraud P, Kantor G, Loiseau H, et al. Target definition in the thorax and central nervous system. Semin Radiat Oncol. 2005;15:146–156
  7. Forgacs E, Zochbauer-Muller S, Olah E, et al. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol Oncol Res. 2001;7:6–13
  8. Siegfried JM, Weissfeld LA, Singh-Kaw P, et al. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer. Cancer Res. 1997;57:433–439
  9. Hu B, Wu L, Han W, et al. The time and spatial effects of bystander response in mammalian cells induced by low dose radiation. Carcinogenesis. 2006;27:245–251
  10. Shuryak I, Sachs RK, Brenner DJ. Biophysical models of radiation bystander effects: 1 (Spatial effects in three-dimensional tissues). Radiat Res. 2007;168:741–749
  11. Ma L, Xia P, Verhey LJ, et al. A dosimetric comparison of fan-beam intensity modulated radiotherapy with gamma knife stereotactic radiosurgery for treating intermediate intracranial lesions. Int J Radiat Oncol Biol Phys. 1999;45:1325–1330
  12. Yi S, Chen JR, Viallet J, et al. Paracrine effects of hepatocyte growth factor/scatter factor on non-small-cell lung carcinoma cell lines. Br J Cancer. 1998;77:2162–2170
  13. Mothersill C, Seymour CB. Cell-cell contact during gamma irradiation is not required to induce a bystander effect in normal human keratinocytes: Evidence for release during irradiation of a signal controlling survival into the medium. Radiat Res. 1998;149:256–262
  14. Rossi L, Reverberi D, Podesta G, et al. Co-culture with human fibroblasts increases the radiosensitivity of MCF-7 mammary carcinoma cells in collagen gels. Int J Cancer. 2000;85:667–673
  15. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–1261
  16. Blazek ER, Foutch JL, Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys. 2007;67:1–5
  17. Bao S, Wu Q, McLendon RE, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444:756–760
  18. Phillips TM, McBride WH, Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006;98:1777–1785
  19. Conger AD. The effect of oxygen on the radiosensitivity of mammalian cells. Radiology. 1956;66:63–69
  20. Du Sault L. Reoxygenation of tumors during fractionated radiotherapy. Radiobiology. 1969;92:626–628
  21. Li C, Wright MM, Jackson RM. Reactive species mediated injury of human lung epithelial cells after hypoxia-reoxygenation. Exp Lung Res. 2002;28:373–389
  22. Petersen C, Zips D, Krause M, et al. Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. Int J Radiat Oncol Biol Phys. 2001;51:483–493
  23. Nakamura K, Brahme A. Evaluation of fractionation regimens in stereotactic radiotherapy using a mathematical model of repopulation and reoxygenation. Radiat Med. 1999;17:219–225
  24. Fujino M, Shirato H, Onishi H, et al. Characteristics of patients who developed radiation pneumonitis requiring steroid therapy after stereotactic irradiation for lung tumors. Cancer J. 2006;12:41–46
  25. Timmerman R, McGarry R, Yiannoutsos C, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–4839
  26. Timmerman R, Bastasch M, Saha D, et al. Optimizing dose and fractionation for stereotactic body radiation therapy (Normal tissue and tumor control effects with large dose per fraction). Front Radiat Ther Oncol. 2007;40:352–365
  27. Dikomey E, Brammer I, Johansen J, et al. Relationship between DNA double-strand breaks, cell killing, and fibrosis studied in confluent skin fibroblasts derived from breast cancer patients. Int J Radiat Oncol Biol Phys. 2000;46:481–490
  28. Geara FB, Peters LJ, Ang KK, et al. Intrinsic radiosensitivity of normal human fibroblasts and lymphocytes after high- and low-dose-rate irradiation. Cancer Res. 1992;52:6348–6352
  29. Bentzen SM. Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol. 1997;43:121–131
  30. Tucker SL, Geara FB, Peters LJ, et al. How much could the radiotherapy dose be altered for individual patients based on a predictive assay of normal-tissue radiosensitivity?. Radiother Oncol. 1996;38:103–113
  31. Rades D, Fehlauer F, Bajrovic A, et al. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol. 2004;70:261–264
  32. Koukourakis MI. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): A new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol. 2002;29(suppl 19):42–46
  33. Le QT, Loo BW, Ho A, et al. Results of a phase I dose-escalation study using single-fraction stereotactic radiotherapy for lung tumors. J Thorac Oncol. 2006;1:802–809
  34. Brenner DJ, Martel MK, Hall EJ. Fractionated regimens for stereotactic radiotherapy of recurrent tumors in the brain. Int J Radiat Oncol Biol Phys. 1991;21:819–824
  35. Fowler JF. The linear-quadratic formula and progress in fractionated radiotherapy. Br J Radiol. 1989;62:679–694
  36. Park C, Papiez L, Zhang S, et al. Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70:847–852

PII: S1053-4296(08)00035-0

doi: 10.1016/j.semradonc.2008.04.006

Seminars in Radiation Oncology
Volume 18, Issue 4 , Pages 244-248 , October 2008

Article Tools